I 
119TH CONGRESS 
1ST SESSION H. R. 6789 
To amend title 18, United States Code, to require the Bureau of Prisons 
to ensure the availability of opioid antagonists at Federal correctional 
facilities. 
IN THE HOUSE OF REPRESENTATIVES 
DECEMBER 17, 2025 
Mrs. FOUSHEE (for herself, Mrs. MCBATH, and Mr. JOHNSON of Georgia) in-
troduced the following bill; which was referred to the Committee on the 
Judiciary 
A BILL 
To amend title 18, United States Code, to require the Bu-
reau of Prisons to ensure the availability of opioid an-
tagonists at Federal correctional facilities. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Federal Prisons 
Naloxone Access Act of 2025’’. 
SEC. 2. AVAILABILITY OF OPIOID ANTAGONISTS. 
Chapter 303 of title 18, United States Code, is 
amended— 
(1) by adding at the end the following: 
VerDate Sep 11 2014 
20:12 Jan 20, 2026
Jkt 069200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H6789.IH
H6789
ssavage on LAPJG3WLY3PROD with BILLS
‘‘§ 4052. Availability of opioid antagonists 
‘‘(a) IN GENERAL.—The Director of the Bureau of 
Prisons shall ensure that— 
‘‘(1) an adequate number of opioid antagonist 
kits are maintained at each correctional facility ad-
ministered by the Bureau, and such kits are avail-
able in— 
‘‘(A) medical housing units; 
‘‘(B) staff breakrooms; and 
‘‘(C) visiting areas, living quarters, recre-
ation spaces, dining halls, housing units, work 
and program locations, hallways, corridor posts, 
security checkpoints, any area where incarcer-
ated people congregate, and educational and re-
ligious areas; 
‘‘(2) that each such opioid antagonist kit is 
maintained appropriately, including storage— 
‘‘(A) in appropriate conditions at room 
temperature and out of direct sunlight; and 
‘‘(B) in a secure area that is accessible to 
personnel of the facility; 
‘‘(3) that incarcerated persons are able to ac-
cess such opioid antagonist kits to administer to 
those who are overdosing; and 
VerDate Sep 11 2014 
20:12 Jan 20, 2026
Jkt 069200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H6789.IH
H6789
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(4) in the case of any opioid antagonist kit 
with an expiration date, that such kit is regularly 
checked to determine if there is a need to replace it. 
‘‘(b) TRAINING.—The Director shall ensure that the 
personnel and incarcerated persons of each correctional fa-
cility administered by the Bureau receive annual training 
from medical staff of the Bureau of Prisons on the admin-
istration of opioid antagonists, including guidance on rec-
ognizing any signs or symptoms of an opioid overdose. 
‘‘(c) DOCUMENTATION.—The Director shall ensure 
that, with regard to each administration of an opioid an-
tagonist at a correctional facility, the following are re-
corded: 
‘‘(1) The location of the administration. 
‘‘(2) The time of the administration. 
‘‘(3) The name of the individual that the opioid 
antagonist was administered to. 
‘‘(4) The name and title of the person that ad-
ministered the opioid antagonist and the status of 
the individual to whom the opioid antagonist was ad-
ministered. 
‘‘(d) NO LIABILITY FOR ADMINISTRATION.—No in-
carcerated person may be held liable for the administra-
tion of an opioid antagonist kit in good faith. 
VerDate Sep 11 2014 
20:12 Jan 20, 2026
Jkt 069200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H6789.IH
H6789
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(e) REPORT.—The Director of the Bureau of Pris-
ons shall submit a report each year to Congress detailing 
compliance with the requirements of this section, includ-
ing— 
‘‘(1) the amount of opioid antagonists available 
at each correctional facility; 
‘‘(2) the number of opioid overdoses at each 
such facility; 
‘‘(3) the number of trainings under subsection 
(b) at each such facility; and 
‘‘(4) the number of expired opioid antagonist 
kits. 
‘‘(f) DEFINITIONS.—In this section: 
‘‘(1) The term ‘opioid antagonist’ means a 
medication approved by the Federal Food and Drug 
Administration that, when administered, neutralizes 
in whole or in part the pharmacological effects of an 
opioid in the human body. 
‘‘(2) The term ‘opioid overdose prevention kit’ 
means a kit containing— 
‘‘(A) an opioid antagonist; and 
‘‘(B) a pamphlet or other written notice 
that provides guidance on how to recognize the 
signs or symptoms of an opioid overdose and 
VerDate Sep 11 2014 
20:12 Jan 20, 2026
Jkt 069200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H6789.IH
H6789
ssavage on LAPJG3WLY3PROD with BILLS
identifies the steps to take in response to a sus-
pected opioid overdose. 
‘‘(3) The term ‘personnel’ includes correctional 
officers, medical staff, counselors, and other employ-
ees of the Bureau of Prisons. 
‘‘(g) AUTHORIZATION OF APPROPRIATIONS.—There 
are authorized to be appropriated: 
‘‘(1) for fiscal year 2026, $6,000,000, for train-
ing, purchase of opioid antagonists, and the initial 
report; 
‘‘(2) for each of fiscal years 2027 and 2028, 
$2,000,000, for maintenance of opioid antagonist 
kits and training, and for additional reporting on the 
effectiveness of the program.’’; and 
(2) in the table of sections for such chapter, by 
adding at the end the following: 
‘‘4052. Availability of opioid antagonists.’’. 
Æ 
VerDate Sep 11 2014 
20:12 Jan 20, 2026
Jkt 069200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\H6789.IH
H6789
ssavage on LAPJG3WLY3PROD with BILLS